Other Events ·
MIRA Pharmaceuticals, Inc. announced on July 6, 2026, positive preclinical study results for the optimized oral…
MIRAMira Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. announced on July 6, 2026, positive preclinical study results for the optimized oral formulation of SKNY-1, an oral drug candidate for obesity and addiction-related disorders. The studies demonstrated favorable oral bioavailability, systemic exposure, and robust brain penetration. MIRA Pharmaceuticals, Inc. is a biopharmaceutical company developing drug candidates for obesity and addiction-related disorders.